Poolbeg Pharma (AIM: POLB) raises £3.5m to fund POLB 001 and oral GLP-1 trials

Poolbeg Pharma plc (AIM: POLB) has conditionally raised £3.5 million before expenses through a placing of 58.3 million new shares at 6p each. The issue price represents a 16.08% discount to the company’s 7.15p closing mid-market price on July 13, 2026. Poolbeg plans to use the proceeds to fund its POLB 001 TOPICAL cancer immunotherapy study and an oral GLP-1 proof-of-concept trial through completion, while extending its expected cash runway into the second quarter of 2028. Executive Chair Cathal Friel participated with a £250,000 investment. The financing reduces near-term funding uncertainty, but the larger share base, placing discount and early clinical stage of both programmes leave execution risk firmly with existing investors.

Why does the £3.5 million placing materially change Poolbeg Pharma’s funding position?

Poolbeg reported that it was debt-free and held approximately £4.8 million in unaudited cash at June 30, 2026. The new placing therefore adds meaningful financial capacity relative to the company’s existing balance sheet, even though the final net proceeds will be lower than the £3.5 million headline amount after transaction expenses.

Management expects the existing resources and placing proceeds to extend the company’s runway into the second quarter of 2028. That is important for a clinical-stage biotechnology company because it allows Poolbeg to progress towards data from two programmes without immediately returning to the market for another routine financing.

The capital is also intended to carry both identified trials through completion, rather than merely funding trial initiation. This should improve visibility over the company’s ability to reach the clinical readouts that could support licensing or development partnerships.

However, a runway into Q2 2028 should not be interpreted as complete funding for every future stage of development. A positive proof-of-concept result could trigger larger studies, regulatory work, manufacturing requirements or additional indication development. Poolbeg’s strategy therefore continues to depend on securing partners or obtaining further capital before expensive late-stage development.

The company has said the financing strengthens its position in ongoing partnering discussions. That is a reasonable strategic objective because a company negotiating with more cash and a funded route to data is generally under less pressure to accept unfavourable terms. It remains an aspiration rather than a disclosed transaction, and no licensing agreement has been announced alongside the placing.

How much dilution will existing Poolbeg Pharma shareholders absorb after admission?

Poolbeg will issue 58,333,328 new ordinary shares under authorities approved at its June 2026 annual general meeting. The shares are expected to be admitted to AIM at 8 am on July 21, subject to the placing conditions being satisfied. The longstop date for admission is August 5.

The new shares represent approximately 8.27% of Poolbeg’s existing issued share capital. Following admission, the total number of shares and voting rights is expected to increase from about 705.1 million to 763,437,106.

Expressed against the enlarged capital base, the placing shares will account for approximately 7.64% of the company. An existing shareholder who does not participate will therefore see a corresponding reduction in proportional ownership.

OAK Securities, the sole bookrunner and newly appointed joint broker, will also receive warrants over 2.75 million shares. These warrants are exercisable at 6p for three years following admission. Full exercise would create modest additional dilution, although it would also bring approximately £165,000 of further capital into the company.

Friel’s £250,000 participation involves the purchase of 4,166,666 placing shares. His holding is expected to rise from 41,056,982 shares to 45,223,648, equal to approximately 5.92% of the enlarged capital. His participation marginally increases his percentage ownership and provides some alignment with shareholders accepting the same 6p issue price.

The placing discount is nevertheless significant. It allowed Poolbeg to complete a financing large enough to fund two trials, but it also transferred part of the near-term risk to existing investors through a lower issue price and larger capital base. The financing creates value only if the additional runway enables clinical or partnering progress worth more than the dilution incurred.

Why is the POLB 001 TOPICAL trial the most immediate value-defining programme?

Despite its name, TOPICAL is not a trial of a topical formulation. It is the acronym for the Trial of Prevention of ImmunoCytokine Adverse events in Myeloma and is evaluating orally administered POLB 001.

POLB 001 is an oral p38 MAP kinase inhibitor being developed to prevent cytokine release syndrome, or CRS, associated with cancer immunotherapies. CRS can occur when treatments activate the immune system so strongly that patients develop fever, cardiovascular instability, organ complications or other potentially life-threatening effects.

The risk of CRS contributes to the need for some cancer immunotherapies to be administered in specialist centres with intensive monitoring capabilities. Poolbeg’s commercial proposition is that preventing or reducing CRS could make treatment safer, reduce hospitalisation requirements and potentially allow more patients to receive therapy closer to home.

The TOPICAL trial is an open-label, single-arm study expected to enrol approximately 30 patients with relapsed or refractory multiple myeloma. Participants will receive POLB 001 twice daily before and during step-up dosing with teclistamab, a bispecific antibody marketed by Johnson & Johnson as Tecvayli.

The first patient was dosed in July, and Poolbeg expects interim data in late summer 2026. The Christie NHS Foundation Trust and University College London Hospitals have activated their study sites, while additional participation is expected from the Royal Marsden, University Hospitals Birmingham, NHS Lothian and Royal Stoke.

Johnson & Johnson is providing teclistamab without charge for the trial. That support reduces part of Poolbeg’s trial burden and demonstrates industry engagement, but it does not constitute a licensing partnership or endorsement of POLB 001’s eventual efficacy.

The trial’s design should allow Poolbeg to obtain an early clinical signal relatively quickly. However, its small size and lack of a randomised control arm mean the results will need careful interpretation. The study can inform safety, biological activity and the feasibility of preventing CRS, but it will not by itself provide the evidence normally required for regulatory approval.

Poolbeg held a pre-investigational new drug meeting with the US Food and Drug Administration in May 2026. The company said it obtained clarity on the nonclinical package, proposed indication, Phase 3 endpoints and potential development route. This may help a future partner assess the programme, although formal regulatory agreement and successful pivotal trials would still be required.

What does the oral GLP-1 proof-of-concept study add to Poolbeg Pharma’s investment case?

Poolbeg’s second funded programme is an oral GLP-1 candidate being developed with AnaBio Technologies. The approach uses proprietary encapsulation technology intended to protect peptide-based treatments from degradation and support delivery through the gastrointestinal system.

The proof-of-concept trial is expected to involve up to 20 participants with obesity at Ulster University. The study will assess safety, tolerability and pharmacokinetics, including whether the formulation can deliver the active ingredient into the body at clinically relevant levels.

This is an important distinction for investors. The initial study is primarily a delivery and pharmacokinetic proof of concept, rather than a large trial designed to establish durable weight loss. A positive result would validate the oral formulation approach and justify further development, while an inconclusive result would weaken the programme before efficacy becomes the central question.

Poolbeg plans to begin the study during the second half of 2026. Management expects the trial to complete relatively quickly once dosing begins, creating another potential data catalyst during the newly funded runway.

The programme gives Poolbeg exposure to the rapidly expanding GLP-1 market without requiring it to compete immediately through a large late-stage obesity trial. A successful oral delivery platform could attract pharmaceutical companies seeking more convenient alternatives to injections or applications beyond a single GLP-1 drug.

The competitive risk is considerable. Multiple large pharmaceutical and biotechnology companies are developing oral incretin therapies, including small molecules and peptide formulations. Poolbeg will need to demonstrate meaningful absorption, acceptable tolerability, practical dosing and a commercially defensible intellectual property position.

Funding the study through completion gives Poolbeg the opportunity to generate that initial evidence. It does not remove the challenge of differentiating the technology in an increasingly crowded market.

How did POLB shares respond to the discounted placing and extended cash runway?

Poolbeg shares had closed at 7.15p before the placing announcement. They subsequently moved towards the 6p issue price, ending the announcement session at approximately 6.05p. That represented a decline of about 15.4%, closely matching the 16.08% discount at which the new shares were placed.

The latest delayed quote on July 15 showed POLB at approximately 6.24p, up 3.14% from the previous close and around 4% above the placing price. The shares were still down approximately 13.3% over five trading days and 17.9% over one month.

Poolbeg’s 52-week range stands between 2.5p and 9p. At 6.24p, the shares were approximately 30.7% below the high but almost 150% above the low. The company’s market capitalisation before admission of the placing shares was approximately £43.5 million.

The immediate price response suggests that the discount established a new short-term valuation anchor. This is common in small-cap biotechnology placings because investors can buy newly issued shares below the preceding market price, while existing holders reassess their proportional exposure.

The more important market test will come when Poolbeg produces clinical data. If POLB 001 generates a credible signal and partnering discussions advance, investors may view the discounted financing as the cost of reaching a major value inflection point. If the studies are delayed, inconclusive or unable to secure partners, the dilution will look more consequential.

Which clinical and partnering milestones will determine whether the financing creates value?

The first milestone is formal admission of the placing shares on or around July 21. Until admission occurs, the fundraise remains conditional rather than fully completed.

The next major catalyst is interim data from the POLB 001 TOPICAL trial, expected in late summer 2026. Investors will focus on safety, the incidence and severity of CRS, patient completion rates and whether the findings support a larger controlled study.

Trial recruitment will also matter. The study involves patients with relapsed or refractory multiple myeloma across several centres, and the timing of interim data depends on enrolment and evaluable patient outcomes.

For the oral GLP-1 programme, the critical near-term milestone is commencement of the proof-of-concept study during the second half of 2026. The subsequent readout must show that the encapsulation technology can achieve useful exposure with an acceptable safety and tolerability profile.

Partnering remains the commercial bridge between early clinical evidence and larger development programmes. Poolbeg has said its data room is active and under review by external parties, including mid-sized and larger pharmaceutical companies. Investors will need to distinguish continued discussions from a signed agreement containing upfront payments, development commitments or milestone economics.

The placing has therefore changed the financial timetable, but not the underlying biotechnology risk. Poolbeg now has more time and sufficient expected resources to generate two important datasets. The quality of those datasets, rather than the length of the runway alone, will determine whether the financing ultimately creates value.

What are the key investor takeaways from Poolbeg Pharma’s £3.5 million placing?

• Poolbeg Pharma conditionally raised £3.5 million before expenses by issuing 58.3 million shares at 6p each.
• The 6p placing price represented a 16.08% discount to the 7.15p closing price immediately before the announcement.
• The company expects the proceeds and existing resources to fund the POLB 001 TOPICAL and oral GLP-1 proof-of-concept trials through completion.
• Poolbeg was debt-free with approximately £4.8 million in unaudited cash at June 30 and now expects a runway into Q2 2028.
• The placing increases the existing share count by 8.27%, while non-participating holders face approximately 7.64% dilution against the enlarged capital base.
• Cathal Friel invested £250,000 and is expected to hold approximately 5.92% of the company following admission.
• POLB 001 interim data are expected in late summer 2026, making the cancer immunotherapy programme the nearest major clinical catalyst.
• The financing reduces immediate funding pressure, but trial outcomes, recruitment, partnering progress and future development costs remain material risks.